Temafloxacin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
|
WikiDoc Resources for Temafloxacin | |
|
Articles | |
|---|---|
|
Most recent articles on Temafloxacin Most cited articles on Temafloxacin | |
|
Media | |
|
Powerpoint slides on Temafloxacin | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Temafloxacin at Clinical Trials.gov Clinical Trials on Temafloxacin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Temafloxacin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Temafloxacin Discussion groups on Temafloxacin Patient Handouts on Temafloxacin Directions to Hospitals Treating Temafloxacin Risk calculators and risk factors for Temafloxacin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Temafloxacin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Temafloxacin (marketed by Abbott Laboratories as Omniflox), is a fluoroquinolone antibiotic drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths.
Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the U.S. by the Food and Drug Administration in January 1992. Severe adverse reactions, including allergic reactions and hemolytic anemia, developed in about fifty patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.
External links
- FDA press release June 5, 1992.
Antibacterials for systemic use: topoisomerase inhibitors - quinolones (J01M) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fluoroquinolones |
| ||||||||
| Other quinolones |
| ||||||||
| †Undergoing clinical trials. ‡ Withdrawn from market. § Veterinary use medications. | |||||||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
